Table 2.
ARV-Naive, % (n) | ARV-Teated, % (n) | |
---|---|---|
Treatment Week 4 | 100 (n=13) | 100 (n=37) |
Treatment Week 12 (end of treatment) | 100 (n=13) | 100 (n=30) |
SVR4 | 100 (n=12) | 100 (n=22) |
SVR12 | 100 (n=10) | pending |
SVR4, sustained viral response at Week 4 posttreatment; SVR12, SVR at Week 12 posttreatment.